Approved for Release: 20	24/02/27 C	06909877
--------------------------	------------	----------

	(b)(3) Inves (b)(6)	RET//NOFORN Inspector Gene tigations Staff ing Memorand		
(b)(3) (b)(6) (b)(7)(c) (b)(3) (b)(6) (b)(7)(c) (b)(3)	1. (S//NF) On 23 August 2013, Office Charge (ASAC) reviewed the review ASAC discovered that on 14 Augu called Var 10 from On 15 August 2013, On 15 August	logfiles fo ust 2013, IP address ugust 2013, the same		 (b)(3) (b)(6) (b)(7)(c) (b)(3) (b)(3) (b)(3) (b)(6)
(b)(3) (b)(1) (b)(3) (b)(6) (b)(7)(c)	 (U//FQLIO) On 23 August 2013, the OIG initiated a preliminary investigation (PI) into the matter. During the course of the PI the reporting agent reviewed the websites and the specific items ordered. The websites identify on the homepage of each that the sites "are offering this very strong alternative to the highly toxic drug listed at the top of the page." identifies Var 10 as associated with the drug oxantrione. A review of the ingredient label for AnVar 10 demonstrated the ingredients as primarily arginine hydrochloride (HCL), multiple amino acids, and vitamin B-6. III. Findings 			

(U//FOUO) The OIG Investigation determined that the products ordered by IP address
 (b)(3) were not schedule III controlled substances. Neither the products nor their ingredients are listed in 21 USC § 802(41)(A) Definitions for steroid associated controlled substances. The investigation also notes that the sites identify that these substances are not "drugs" and are alternatives to actual steroids. This matter is considered closed by OIG.

IV. Review and Approval	(b)(3) (b)(6)	
Case Closing Memo submitted by Investigator to Supervisor:	(b)(7)(c)	/12/293
Case Closing Memo approved by Supervisor:	(b)(3) (b)(6) (b)(7)(c)	10/H/2013
This document is controlled by the CIA/OIG and neithe	r the document nor its conten	INV-201 Page 1 of 1 ts should be

disseminated without prior IG authorization.

(b)(3)

SECRET //NOFORN